Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Impedimed Limited ( (AU:IPD) ) just unveiled an announcement.
In its latest quarterly report, ImpediMed Limited announced record revenue of A$3.3 million and cash receipts of A$3.4 million for the quarter ending December 2024. The company reported significant growth in payor coverage, with reimbursement increasing to 75% of the US population, highlighting a strategic focus on expanding its market presence. The report also noted a strong pipeline for its SOZO units, a low churn rate, and an increase in annual recurring revenue. Despite a decrease in total contracted value, ImpediMed highlighted the quality of renewed accounts and successful price increases. Overall, the financial results reflect a positive trajectory in operational performance and market strategy, with implications for strengthened industry positioning and enhanced investor confidence.
More about Impedimed Limited
ImpediMed Limited operates in the medical technology industry, providing products and services focused on bioimpedance spectroscopy, particularly for the detection and monitoring of lymphedema. The company targets healthcare providers and patients, with a significant emphasis on expanding reimbursement coverage for its SOZO device, which measures fluid status and tissue composition.
YTD Price Performance: 0.0%
Average Trading Volume: 31,879
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $68.19M
Find detailed analytics on IPD stock on TipRanks’ Stock Analysis page.
